Literature DB >> 21510306

Suspected interaction between sorafenib and HAART in an HIV-1 infected patient: a case report.

Violaine Ozenne1, Anne Gervais, Gilles Peytavin, Corrine Castelnau, Dominique Charles Valla, Françoise Degos.   

Abstract

Sorafenib prolongs survival of patients with unresectablehepatocellular carcinoma (HCC). It is likely to be used in human immunodeficiency virus (HIV) infected patients. Interactions between sorafenib and highly active antiretroviral therapy (HAART) have not been studied yet. We report a case of serious adverse effects in anHIV-1 patient co-infected with HBV.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21510306

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN： 0172-6390


  5 in total

1.  Clinical Outcomes Associated with Drug-Drug Interactions of Oral Chemotherapeutic Agents: A Comprehensive Evidence-Based Literature Review.

Authors:  Manvi Sharma; Aisha Vadhariya; Soumya Chikermane; Suma Gopinathan; Mariana Chavez-MacGregor; Sharon H Giordano; Michael L Johnson; Holly M Holmes
Journal:  Drugs Aging       Date:  2019-04       Impact factor: 3.923

Review 2.  Hepatitis B virus coinfection in human immunodeficiency virus-infected patients: a review.

Authors:  Hsin-Yun Sun; Wang-Huei Sheng; Mao-Song Tsai; Kuan-Yeh Lee; Sui-Yuan Chang; Chien-Ching Hung
Journal:  World J Gastroenterol       Date:  2014-10-28       Impact factor: 5.742

3.  A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi Sarcoma.

Authors:  Thomas S Uldrick; Priscila H Gonçalves; Kathleen M Wyvill; Cody J Peer; Wendy Bernstein; Karen Aleman; Mark N Polizzotto; David Venzon; Seth M Steinberg; Vickie Marshall; Denise Whitby; Richard F Little; John J Wright; Michelle A Rudek; William D Figg; Robert Yarchoan
Journal:  Oncologist       Date:  2017-03-24

Review 4.  Loco-Regional Treatments for Hepatocellular Carcinoma in People Living with HIV.

Authors:  Cristina Micali; Ylenia Russotto; Grazia Caci; Manuela Ceccarelli; Andrea Marino; Benedetto Maurizio Celesia; Giovanni Francesco Pellicanò; Giuseppe Nunnari; Emmanuele Venanzi Rullo
Journal:  Infect Dis Rep       Date:  2022-01-07

5.  Treatment of Recurrent Hepatocellular Carcinoma with Sorafenib in a HIV/HCV Co-Infected patient in HAART: A Case Report.

Authors:  Pasquale De Nardo; Magdalena Viscione; Angela Corpolongo; Rita Bellagamba; Giovanni Vennarecci; Giuseppe Maria Ettorre; Elisa Gentilotti; Chiara Tommasi; Emanuele Nicastri
Journal:  Infect Agent Cancer       Date:  2012-06-28       Impact factor: 2.965
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.